{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:01:59Z","timestamp":1781308919061,"version":"3.54.1"},"reference-count":19,"publisher":"Cambridge University Press (CUP)","issue":"4","license":[{"start":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T00:00:00Z","timestamp":1413763200000},"content-version":"unspecified","delay-in-days":111,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:sec id=\"S0317167100018461_abs1\"><jats:title>Background:<\/jats:title><jats:p>Vinca alkaloids and platinum-containing chemotherapeutic drugs have the potential to cause chemotherapy-induced peripheral neuropathy (CIPN). This study determined the frequency of CIPN among children who were treated for acute lymphoblastic leukemia (ALL), lymphoma, brain tumour or Wilms tumour.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167100018461_abs2\"><jats:title>Procedure:<\/jats:title><jats:p>This retrospective cohort study reviewed 252 patients treated at the Children's hospital of Eastern Ontario from 2001-2011. Patients were considered to have CIPN if they developed clinical symptoms of CIPN such as limb paraesthesia, weakness and\/or ataxia during chemotherapy and their treating neurologist or oncologist deemed that their symptoms were due to a peripheral cause. Patients were excluded if their treatment regime did not include chemotherapy.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167100018461_abs3\"><jats:title>Results:<\/jats:title><jats:p>The overall frequency of CIPN was 18.3% (46\/252). Tumour-specific CIPN rates were: 18.9% (29\/154) for ALL; 9.4% (3\/32) for lymphoma; 17.9% (5\/28) for Wilms tumour; and 23.7% (9\/38) for brain tumour patients. Nerve conduction studies were completed for 17% of patients (all tumour types) and were abnormal in all but one patient. Among surviving CIPN patients (41\/46), 93% showed no clinical deficits at their last examination, which was on average 56 months from time of diagnosis to last follow-up visit.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167100018461_abs4\"><jats:title>Conclusions:<\/jats:title><jats:p>The frequency of CIPN was less than that previously reported in adults receiving chemotherapy. Children with CIPN have a favourable outcome with most showing clinical improvement during the maintenance phase of treatment or after chemotherapy completion.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s0317167100018461","type":"journal-article","created":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T16:25:29Z","timestamp":1417537529000},"page":"442-447","source":"Crossref","is-referenced-by-count":27,"title":["Chemotherapy-induced Peripheral Neuropathy Among Paediatric Oncology Patients"],"prefix":"10.1017","volume":"41","author":[{"given":"M.J.","family":"Purser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2014,10,20]]},"reference":[{"key":"S0317167100018461_ref007","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000154642.45474.28"},{"key":"S0317167100018461_ref001","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2012.02.011"},{"key":"S0317167100018461_ref018","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10503"},{"key":"S0317167100018461_ref013","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050968"},{"key":"S0317167100018461_ref008","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21706"},{"key":"S0317167100018461_ref005","first-page":"323","article-title":"Clinical and electrophysiological studies in vincristine induced neuropathy","volume":"39","author":"Pal","year":"1999","journal-title":"Electromyogr Clin Neurophysiol"},{"key":"S0317167100018461_ref004","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.04.018"},{"key":"S0317167100018461_ref003","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21435"},{"key":"S0317167100018461_ref002","first-page":"1","article-title":"Acute and long-term neurologic complications in children with acute lymphoblastic leukemia","volume":"48","author":"Aytac","year":"2006","journal-title":"Turk J Pediatr"},{"key":"S0317167100018461_ref011","doi-asserted-by":"publisher","DOI":"10.1007\/BF02223095"},{"key":"S0317167100018461_ref012","doi-asserted-by":"publisher","DOI":"10.1007\/BF00255487"},{"key":"S0317167100018461_ref017","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26337"},{"key":"S0317167100018461_ref016","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200304000-00010"},{"key":"S0317167100018461_ref015","doi-asserted-by":"publisher","DOI":"10.1053\/ejpn.1999.0310"},{"key":"#cr-split#-S0317167100018461_ref009.1","unstructured":"1. U.S. Department of Health and Human Services [homepage on the internet]. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 [updated 2010 June 14 2. cited 2013 Sep 17]. Available from: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf"},{"key":"#cr-split#-S0317167100018461_ref009.2","doi-asserted-by":"crossref","unstructured":"cited 2013 Sep 17]. Available from: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf","DOI":"10.2118\/0310-014-TWA"},{"key":"S0317167100018461_ref010","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/96.1.69"},{"key":"S0317167100018461_ref014","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23039"},{"key":"S0317167100018461_ref006","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22845"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167100018461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T18:34:47Z","timestamp":1650738887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167100018461\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0317167100018461"],"URL":"https:\/\/doi.org\/10.1017\/s0317167100018461","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}